Taiwan · Delayed Price · Currency is TWD Sofiva Genomics Statistics
Total Valuation
Sofiva Genomics has a market cap or net worth of TWD 712.58 million. The enterprise value is 623.54 million.
| Market Cap | 712.58M |
| Enterprise Value | 623.54M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Jun 27, 2025 |
Share Statistics
Sofiva Genomics has 21.59 million shares outstanding. The number of shares has decreased by -0.49% in one year.
| Current Share Class | 21.59M |
| Shares Outstanding | 21.59M |
| Shares Change (YoY) | -0.49% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 5.59% |
| Owned by Institutions (%) | n/a |
| Float | 12.64M |
Valuation Ratios
The trailing PE ratio is 84.95.
| PE Ratio | 84.95 |
| Forward PE | n/a |
| PS Ratio | 1.86 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | 26.49 |
| P/OCF Ratio | 25.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.49, with an EV/FCF ratio of 23.18.
| EV / Earnings | 74.34 |
| EV / Sales | 1.63 |
| EV / EBITDA | 13.49 |
| EV / EBIT | 71.26 |
| EV / FCF | 23.18 |
Financial Position
The company has a current ratio of 3.47, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.47 |
| Quick Ratio | 2.87 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 2.60 |
| Debt / FCF | 1.19 |
| Interest Coverage | -33.00 |
Financial Efficiency
Return on equity (ROE) is 1.39% and return on invested capital (ROIC) is -3.70%.
| Return on Equity (ROE) | 1.39% |
| Return on Assets (ROA) | -2.11% |
| Return on Invested Capital (ROIC) | -3.70% |
| Return on Capital Employed (ROCE) | -3.79% |
| Weighted Average Cost of Capital (WACC) | 5.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.52 |
| Inventory Turnover | 7.33 |
Taxes
In the past 12 months, Sofiva Genomics has paid 2.17 million in taxes.
| Income Tax | 2.17M |
| Effective Tax Rate | 19.57% |
Stock Price Statistics
The stock price has increased by +2.96% in the last 52 weeks. The beta is 0.21, so Sofiva Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +2.96% |
| 50-Day Moving Average | 33.39 |
| 200-Day Moving Average | 32.10 |
| Relative Strength Index (RSI) | 50.29 |
| Average Volume (20 Days) | 27,339 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sofiva Genomics had revenue of TWD 382.82 million and earned 8.39 million in profits. Earnings per share was 0.39.
| Revenue | 382.82M |
| Gross Profit | 100.64M |
| Operating Income | -25.15M |
| Pretax Income | 11.07M |
| Net Income | 8.39M |
| EBITDA | 1.40M |
| EBIT | -25.15M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 120.89 million in cash and 32.08 million in debt, with a net cash position of 88.81 million or 4.11 per share.
| Cash & Cash Equivalents | 120.89M |
| Total Debt | 32.08M |
| Net Cash | 88.81M |
| Net Cash Per Share | 4.11 |
| Equity (Book Value) | 642.44M |
| Book Value Per Share | 29.76 |
| Working Capital | 164.08M |
Cash Flow
In the last 12 months, operating cash flow was 28.02 million and capital expenditures -1.13 million, giving a free cash flow of 26.90 million.
| Operating Cash Flow | 28.02M |
| Capital Expenditures | -1.13M |
| Depreciation & Amortization | 26.54M |
| Net Borrowing | -14.63M |
| Free Cash Flow | 26.90M |
| FCF Per Share | 1.25 |
Margins
Gross margin is 26.29%, with operating and profit margins of -6.57% and 2.19%.
| Gross Margin | 26.29% |
| Operating Margin | -6.57% |
| Pretax Margin | 2.89% |
| Profit Margin | 2.19% |
| EBITDA Margin | 0.36% |
| EBIT Margin | -6.57% |
| FCF Margin | 7.03% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 0.91%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 0.91% |
| Dividend Growth (YoY) | 50.77% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 77.23% |
| Buyback Yield | 0.49% |
| Shareholder Yield | 1.40% |
| Earnings Yield | 1.18% |
| FCF Yield | 3.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |